Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis.
Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis. — المؤلف: Ginsberg, Gary M — Israel journal of health policy research 20190617
- المؤلف
- Ginsberg, Gary M
- النشر
- Israel journal of health policy research 20190617
- الوصف
- 63 p.
- الموضوعات
- Antiviral Agents؛ Cost-Benefit Analysis؛ Hospitalization؛ Humans؛ Immunization؛ Infant؛ Israel؛ Palivizumab